BioMerieux Free Cash Flow 2017-2023 | BMXMF

BioMerieux free cash flow for the twelve months ending December 31, 2023 was , a year-over-year.

  • BioMerieux annual free cash flow for 2023 was $0.123B, a 43.35% decline from 2022.
  • BioMerieux annual free cash flow for 2022 was $0.217B, a 66.12% decline from 2021.
  • BioMerieux annual free cash flow for 2021 was $0.64B, a 69.79% increase from 2020.

BioMerieux Free Cash Flow 2017-2023 | BMXMF

  • BioMerieux annual free cash flow for 2023 was $0.123B, a 43.35% decline from 2022.
  • BioMerieux annual free cash flow for 2022 was $0.217B, a 66.12% decline from 2021.
  • BioMerieux annual free cash flow for 2021 was $0.64B, a 69.79% increase from 2020.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$96B
Cencora (COR)$46.2B
DiDi Global (DIDIY)$23.8B
ICON (ICLR)$18.2B
Natera (NTRA)$15.4B
Avantor (AVTR)$15.2B
Revvity (RVTY)$14.9B
Viatris (VTRS)$13.9B
Solventum (SOLV)$12.5B
CochLear (CHEOY)$12.3B
Medpace Holdings (MEDP)$9.9B
Charles River Laboratories (CRL)$9.3B
Sonic Healthcare (SKHHY)$8.4B
Doximity (DOCS)$7.9B
HealthEquity (HQY)$7.5B
Bausch + Lomb (BLCO)$7.2B
PACS (PACS)$6.5B
Life Times (LTH)$4.7B
Organon (OGN)$4.7B
Sotera Health (SHC)$4.5B
Surgery Partners (SGRY)$3.7B
BrightSpring Health Services (BTSG)$3B
Concentras Parent (CON)$2.5B
Ardent Health Partners (ARDT)$2.5B
Alignment Healthcare (ALHC)$2.5B
GoodRx Holdings (GDRX)$2.3B
GeneDx Holdings (WGS)$2.1B
Premier (PINC)$2B
Ryman Healthcare (RYHTY)$1.9B
Teladoc Health (TDOC)$1.6B